Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Indivior PharmaceuticalsINDV +0.02%69 EV-to-EBITDA is 14.48 as of Jul. 25, 2026, which is 90% above its 10-year median of 7.61. GuruFocus rates INDV with a GF Score™ of 69/100 and a GF Value™ of $22.90 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 742 Drug Manufacturers companies, Indivior Pharmaceuticals ranks worse than 55.26% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Indivior Pharmaceuticals's enterprise value is $5,127 Mil.
Indivior Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $354 Mil. Therefore, Indivior Pharmaceuticals's EV-to-EBITDA for today is 14.48.
The historical rank and industry rank for Indivior Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
INDV'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -132 Med: 7.61 Max: 25.93
Current: 14.48
During the past 13 years, the highest EV-to-EBITDA of Indivior Pharmaceuticals was 25.93. The lowest was -132.00. And the median was 7.61.
INDV's EV-to-EBITDA is ranked worse than 55.26% of 742
companies
in the Drug Manufacturers industry
Industry Median: 12.96
vs INDV: 14.48
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Indivior Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Indivior Pharmaceuticals's share price for today is $40.55.
Indivior Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.950.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Indivior Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Indivior Pharmaceuticals EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Indivior Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Indivior Pharmaceuticals's EV-to-EBITDA falls into.
Indivior Pharmaceuticals's current Enterprise Value is $5,127 Mil.
Indivior Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $354 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Indivior Pharmaceuticals (INDV) has a EV-to-EBITDA of 14.48 as of Jul. 25, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Indivior Pharmaceuticals. This is 90% above median its historical median of 7.61. According to the industry distribution chart, Indivior Pharmaceuticals ranks #410 out of 742 companies in the Drug Manufacturers industry, placing it in the top 55.3%.
Is Indivior Pharmaceuticals' EV-to-EBITDA too high?
Indivior Pharmaceuticals' current EV-to-EBITDA of 14.48 is 90% above median its 10-year median of 7.61. The Drug Manufacturers industry median EV-to-EBITDA is 12.96. Indivior Pharmaceuticals' value of 14.48 is 11.7% above this industry median. Based on the distribution chart, Indivior Pharmaceuticals ranks #410 out of 742 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Indivior Pharmaceuticals has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Indivior Pharmaceuticals' EV-to-EBITDA compare to KNSA and AMRX?
According to the Drug Manufacturers industry distribution chart, Indivior Pharmaceuticals ranks #410 out of 742 companies for EV-to-EBITDA. This places Indivior Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBITDA is 12.96. Indivior Pharmaceuticals' value of 14.48 is 11.7% above this benchmark. While the company's 10-year median is 7.61 vs. the industry median of 12.96, Indivior Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.96, based on 742 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Indivior Pharmaceuticals's current EV-to-EBITDA of 14.48 is 11.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Indivior Pharmaceuticals. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Indivior Pharmaceuticals's current EV-to-EBITDA is 14.48, which is 90% above median its own 10-year median of 7.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indivior Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Indivior Pharmaceuticals (INDV) is currently considered Significantly Overvalued. The stock's GF Value™ is $22.90, compared to a current price of $40.55 — trading 77.1% above its estimated fair value. The current EV-to-EBITDA is 14.48, which is 90% above median its 10-year median of 7.61 and 11.7% above the Drug Manufacturers industry median of 12.96. Indivior Pharmaceuticals' overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Indivior Pharmaceuticals (INDV), the current EV-to-EBITDA is 14.48 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Indivior Pharmaceuticals (INDV) Overvalued in 2026?
Based on GuruFocus' analysis, Indivior Pharmaceuticals stock appears to be overvalued.
The current stock price of $40.55 is trading 77.1% above its estimated GF Value™ of $22.90.
GuruFocus considers Indivior Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for INDV:
EV-to-EBITDA: 14.48 (90% above median its 10-year median of 7.61)
GF Value™: $22.90 vs. price of $40.55 (77.1% above fair value)
Industry Position: 11.7% above the Drug Manufacturers median (#410 of 742)
No single metric tells the full story. See the INDV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
69GF Score
Get the complete analysis for INDV
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INDV has been successfully added to your 
